Drug
Bnt162b2 Vaccine
Bnt162b2 Vaccine: highest development phase Post-Market, developed by BioNTech. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT162b2 Vaccine NCT07730450 | Post-Market | COVID-19 Vaccines |
| BNT162b2 Vaccine NCT07300839 | Phase 3 | COVID-19 |
Latest
No recent events.
Follow Bnt162b2 Vaccine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.